Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8741881 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8729057 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8754070 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8466136 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8759329 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8486925 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8466138 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8466137 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 April, 2011
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(24 days from now) | |
US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(24 days from now) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(1 year, 11 months from now) |
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Market Authorisation Date: 15 December, 2008
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic